Intellia Therapeutics, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $7.7 million (-46.2% year over year) and diluted EPS of -$0.80. It usually reports 30–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
8
-46.2%
|
-107
-5.3%
|
-0.80
+18.4%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
15
-9.5%
|
-96
+15.8%
|
-0.81
+26.4%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
23
+78.8%
|
-96
+25.7%
|
-0.83
+34.7%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
14
+51.3%
|
-101
+25.3%
|
-0.92
+31.3%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
14
+104.8%
|
-101
+31.1%
|
-0.98
+35.5%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
17
-42.5%
|
-114
-6.4%
|
-1.10
+1.8%
|
|
Jan 10, 2025
10 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
13
+771.6%
|
-129
+2.5%
|
-1.27
+13.4%
|
|
Nov 7, 2024
38 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NTLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1652130
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.